SMIs & Soft Mist Nasal Sprays – A key defence in the fight against the next pandemic?

Authors: Wilbur de Kruif

Publication: International Pharmaceutical Industry, Volume 14(2), 2022

Abstract: The COVID-19 outbreak has provided a number of lessons for the pharmaceutical industry to consider for future pandemics. Could soft mist inhalers (SMIs), and soft mist nasal sprays in particular, hold the key to improved vaccine delivery?

Biologic vaccines are highly sensitive, and conventional nasal devices can compromise formulation integrity or fail to deliver consistent doses. Next-generation soft mist inhalers (SMIs) and soft mist nasal sprays address these challenges through controlled plume dynamics, narrow spray cone angles, and biologic-compatible nozzle designs that enhance deposition in the upper nasal cavity while minimising particle damage.

Built on modular, standardised platforms, these devices also streamline development, reduce customisation needs, and support faster regulatory and commercialisation timelines. As a result, SMIs and soft mist nasal sprays offer a practical, scalable route to unlocking the full potential of nasal vaccines—strengthening global preparedness and enabling more efficient, accessible vaccination strategies for future pandemics.

Find out more in our article.